4.7 Review

Drugging the HDAC6-HSP90 interplay in malignant cells

Journal

TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 35, Issue 10, Pages 501-509

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2014.08.001

Keywords

Acetylation; cancer; HDAC6; HDAC6 inhibitor; HSP90; leukemia

Funding

  1. Deutsche Forschungsgemeinschaft [KR 2291/4-1/MA 2183/1-1]
  2. German Cancer Aid [110909, 110125]
  3. Wilhelm Sander-Stiftung [2010.078.2]
  4. intramural fundings

Ask authors/readers for more resources

Acetylation and deacetylation cycles regulate crucial biological processes. The enzymes deacetylating lysine residues are termed histone deacetylases (HDACs). Eighteen deacetylases have been isolated from mammalian cells. There is an intense search underway for individual functions of these enzymes and for selective histone deacetylase inhibitors (HDACi). HDAC6 in particular has unique cytoprotective functions that rely on its ability to ensure protein homeostasis and to prevent protein aggregation. The chaperone heat shock protein 90 (HSP90) also safeguards proteins and is deacetylated by HDAC6. Current data illustrate the complexity and importance of the HDAC6-HSP90 interplay. In this review, we discuss how recently identified HSP90-dependent regulators of post-translational modifications (PTMs) of HDAC6 dictate its functions, and how HDACi-induced acetylation of HSP90 might control oncologically relevant proteins, especially in leukemic cells. Additionally, we discuss small molecules blocking HDAC6 and how such agents could become therapeutically relevant. We summarize structure-function relationships that determine the specificity of drugs against HDAC6.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available